Literature DB >> 28244476

Incidence of prostate cancer at a single tertiary care center in North Karnataka.

S C Ghagane1, R B Nerli2, M B Hiremath1, A T Wagh2, P V Magdum2.   

Abstract

CONTEXT: Prostate cancer (PC) remains one of the most common cancers affecting men today. Thus, understanding the prevalence, disease characteristics, and changing demographics of Indian PC patients has emerged as an important aspect of study. AIMS: We aimed to present the case series of PC patients from single tertiary care center in North Karnataka. SETTINGS AND
DESIGN: The study designed over a period of 8 years from 2007 to 2015 was conducted in the Department of Urology, KLES Dr. Prabhakar Kore Hospital, Belagavi, Karnataka.
MATERIALS AND METHODS: A total of 471 newly diagnosed patients with PC from 2007 to 2015 were included in the study. Sociodemographic, clinical characteristics, radiological and histopathological findings of all patients were collected and analyzed for the risk of PC. STATISTICAL ANALYSIS USED: The statistical analysis used in this study was IBM SPSS Statistics software Inc., version 20.0.
RESULTS: A total of 471 patients were diagnosed with PC, the mean age at presentation was 70 years, and mean prostate-specific antigen (PSA) level was 37.71 ng/mL. Digital rectal examination (DRE) was abnormal in 87.5% of 471 cases. Significant correlation was observed between PSA level and DRE (P = 0.0005), correlation of PSA and Gleason's score was P = 0.0006, and histopathological results showed high risk in patients (P = 0.0001).
CONCLUSIONS: This is the first hospital-based study of PC incidence with clinical and histopathological features. PC remains an important public health problem with increasing incidence and significant burden on health-care resources in India.

Entities:  

Mesh:

Year:  2016        PMID: 28244476     DOI: 10.4103/0019-509X.200671

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  7 in total

1.  Evaluation of Biochemical Recurrence and Correlation with Various Parameters After Robotic-Assisted Radical Prostatectomy: a Single Center Experience.

Authors:  Mahendra Singh; Sachin Kathuria; Saurabh Jain; Shahnawaz Rasool; Vipin Tyagi; Manu Gupta; Mrinal Pahwa; Himanshu Pandey; Ajay Sharma
Journal:  Indian J Surg Oncol       Date:  2022-05-14

2.  CRTC2 as a novel prognostic biomarker for worse pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with prostate cancer.

Authors:  Hakmin Lee; Minseung Lee; Sung Kyu Hong
Journal:  Investig Clin Urol       Date:  2019-02-19

3.  Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets.

Authors:  Amol Patel; Ian F Tannock; Priyanka Srivastava; Bivas Biswas; Vineet Govinda Gupta; Atul Batra; Sainath Bhethanabhotla; Raja Pramanik; Shubh Mahindru; Tvsvgk Tilak; Chandan Krishna Das; Prashant Mehta
Journal:  JCO Glob Oncol       Date:  2020-03

4.  Hypoehoic lesions on Transrectal Ultrasound and its correlation to Gleason grade in the diagnosis of Clinically Significant Prostate Cancer: A Prospective Study.

Authors:  Manas Sharma; Rajendra B Nerli; Sree Harsha Nutalapati; Shridhar C Ghagane
Journal:  South Asian J Cancer       Date:  2021-11-11

5.  Voided urine test to diagnose prostate cancer: Preliminary report.

Authors:  R B Nerli; Shridhar C Ghagane; Saziya R Bidi; Madhukar L Thakur; Leonard Gomella
Journal:  Cytojournal       Date:  2021-10-02       Impact factor: 2.091

6.  Role of 68Ga-PSMA-PET/CT for the detection of primary prostate cancer prior to biopsy: a prospective study.

Authors:  Harsh Jain; Rajeev Sood; Mohammad Shazib Faridi; Hemant Goel; Umesh Sharma
Journal:  Cent European J Urol       Date:  2021-07-08

7.  MicroRNA-596 is epigenetically inactivated and suppresses prostatic cancer cell growth and migration via regulating Wnt/β-catenin signaling.

Authors:  J Dai; G Yuan; Y Li; H Zhou
Journal:  Clin Transl Oncol       Date:  2021-01-02       Impact factor: 3.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.